Core Insights - The average stock price of A-shares is 13.64 yuan, with 28 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.38 yuan [1][2] - Among the low-priced stocks, 13 are ST stocks, accounting for 46.43% of the total [1] - In terms of market performance, 23 of the low-priced stocks increased in price, with Yingxin Development, Rongsheng Development, and Guangtian Group leading with gains of 10.00%, 5.06%, and 4.49% respectively [1] Low-Priced Stocks Overview - The lowest priced stock is *ST Gao Hong at 0.38 yuan, followed by *ST Su Wu at 0.97 yuan and *ST Yuan Cheng at 1.16 yuan [1] - The table of low-priced stocks includes various sectors such as telecommunications, pharmaceuticals, construction decoration, and real estate [1][2] - Notable daily price changes include Yingxin Development with a 10.00% increase and *ST Yuan Cheng with a 4.92% decrease [1][2]

Group 1 - Hongbo Co., Ltd. (002229) is currently facing investor compensation lawsuits due to false statements, with some investors already winning judgments [1] - The company announced a significant revision of its 2023 profit forecast, changing from an expected profit of 37.4 million to 56.1 million yuan to a projected loss of 50 million to 58 million yuan [1] - The China Securities Regulatory Commission (CSRC) issued a warning letter to Hongbo Co., Ltd. for violating the Information Disclosure Management Measures for Listed Companies [1] Group 2 - Attorney Xu Feng is representing investors in the Jiangsu Wuzhong (600200) compensation case, which has also been submitted to the Suzhou Intermediate People's Court [2] - Jiangsu Wuzhong is accused of failing to disclose the actual controller and inflating revenue, costs, and profits in its annual reports from 2020 to 2023 [3][4] - Investors who purchased Jiangsu Wuzhong shares between April 20, 2019, and February 27, 2025, may also initiate compensation claims [4]

Core Points - The average stock price of A-shares is 13.43 yuan, with 31 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.38 yuan [1] - As of October 20, the Shanghai Composite Index closed at 3863.89 points, indicating a relatively small proportion of both high-priced and low-priced stocks in the A-share market [1] Low-Priced Stocks Overview - Among the 31 low-priced stocks, 14 are ST stocks, accounting for 45.16% of this group [1] - In terms of market performance, 25 of the low-priced stocks increased in price, with notable gains from Yingxin Development (9.76%), ST Lingnan (5.16%), and HNA Holding (3.57%) [1] - The two stocks that declined were *ST Yuan Cheng and *ST Jin Ke, with decreases of 4.69% and 0.72%, respectively [1] Detailed Low-Priced Stocks Data - The table lists various low-priced stocks, including their latest closing prices, daily price changes, turnover rates, price-to-book ratios, and industries [1][2] - For example, *ST Gao Hong has a closing price of 0.38 yuan and a price-to-book ratio of 0.99, while *ST Su Wu is priced at 0.97 yuan with a price-to-book ratio of 0.39 [1][2]

一、公司股票可能被终止上市的原因 根据《股票上市规则》第 9.2.1 条第一款的规定：在上交所仅发行 A 股股票 的上市公司，如果连续 20 个交易日的每日股票收盘价均低于 1 元，公司股票可 能被上交所终止上市交易。公司股票 2025 年 10 月 17 日收盘价为 0.97 元/股， 低于人民币 1 元。如果出现"连续 20 个交易日的每日股票收盘价均低于人民币 1 元"的情形，公司股票可能被上交所终止上市交易。 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-123 江苏吴中医药发展股份有限公司关于公司股票 可能存在因股价低于 1 元而终止上市的风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先告知书》（处 罚字〔2025〕58 号），认定公司虚增营业收入、营业成本和利润，2020-2023 年年度报告存在虚假记载。上述事项触及《上海证券交易所股票上市规则》第 9.5.2 条第一款第（六）项规定的重大违法强 ...

Core Insights - The average stock price in the A-share market is 13.33 yuan, with 31 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.38 yuan [1] - Among the low-priced stocks, 14 are ST stocks, accounting for 45.16% of the total [1] - The market performance shows that out of the low-priced stocks, 4 increased in price while 25 decreased, with *ST Yuan Cheng experiencing the largest drop of 5.19% [1] Low-Priced Stocks Overview - The lowest priced stock is *ST Gao Hong at 0.38 yuan, with a price-to-book ratio of 0.99 and belonging to the telecommunications industry [1] - *ST Yuan Cheng and *ST Su Wu follow with closing prices of 1.28 yuan and 0.97 yuan, respectively, with *ST Yuan Cheng having a price-to-book ratio of 0.58 [1] - The highest daily increase among low-priced stocks was seen in *ST Hui Feng, which rose by 2.60% [1] Market Performance - The Shanghai Composite Index closed at 3839.76 points as of October 17 [1] - The majority of low-priced stocks experienced declines, with notable drops in *ST Yuan Cheng (-5.19%), Jinyu Group (-3.37%), and ST Lingnan (-3.13%) [1] - The trading volume varied, with *ST Su Wu showing a turnover rate of 3.50% while *ST Yuan Cheng had a lower turnover rate of 0.13% [1]

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to significant illegal delisting risks for the company's stock [2][4][6]. Group 1: Investigation and Regulatory Actions - The company received a notice of investigation from the CSRC on February 26, 2025, due to suspected violations of information disclosure laws [4]. - On July 13, 2025, the company was issued a preliminary administrative penalty notice by the CSRC, which identified inflated operating income, costs, and profits in annual reports from 2020 to 2023 [5]. - The company’s stock has been subject to significant illegal delisting risk warnings since July 14, 2025, following the CSRC's findings [2][5]. Group 2: Financial Irregularities - The company inflated its operating income by amounts ranging from 37.67 million to 49.53 million yuan from 2020 to 2023, representing 16.82% to 26.46% of the reported operating income for those years [5]. - Operating costs were also inflated by 35.54 million to 48.07 million yuan, accounting for 20.95% to 37.08% of the reported operating costs during the same period [5]. - The total profit was inflated by 1.46 million to 2.12 million yuan, which constituted 2.89% to 51.65% of the reported profit for the respective years [5]. Group 3: Additional Risks - The company faces multiple delisting risks, including financial delisting and risks related to the freezing of shares held by the controlling shareholder [3][8]. - As of the end of 2023, the controlling shareholder's related parties had non-operating fund occupation amounting to 169.26 million yuan, which remains unresolved [8]. - The company reported a net loss of 44.42 million yuan for the first half of 2025, a decline of 281.63% compared to the same period last year [9].

Core Insights - The domestic medical beauty market in China is becoming increasingly competitive, with significant price reductions and patent disputes among leading companies [1][3][6] - Major players are expanding overseas as domestic profit margins shrink, indicating a strategic shift towards international markets [1][11] Market Competition - New Oxygen launched a low-priced "Miracle Youth Needle" at 2999 yuan, significantly undercutting competitors and causing dissatisfaction among upstream material suppliers [3][6] - Huaxi Biological and Juzi Biological are engaged in a fierce dispute over collagen product patents, highlighting the intense competition in the market [3][4] - The competition is characterized by a shift from regulatory competition to market-driven competition, with a growing number of brands entering the space [6][7] Financial Performance - Major companies like Aimeike and Huaxi Biological reported significant declines in revenue and net profit, with Aimeike's revenue and net profit down 21.59% and 29.57% respectively in the first half of the year [7][10] - Huaxi Biological's revenue and net profit also fell by 19.57% and 35.38% respectively, marking a continuous decline over two years [7][10] International Expansion - Chinese medical beauty companies are increasingly looking to international markets, with firms like Aimeike and Huaxi Biological investing in overseas partnerships [1][11] - The strategy involves acquiring or investing in foreign companies to introduce Chinese products to international markets, rather than relying on traditional business development methods [11][12] Emerging Markets - There is a growing opportunity in emerging markets such as Southeast Asia and Latin America, where demand for cost-effective and multifunctional products is rising [12][13] - Companies are focusing on building technological barriers and moving away from the "low-price" label by investing in advanced materials and techniques [13]

Core Viewpoint - The A-share market is experiencing an unprecedented wave of delistings due to major violations, with a record number of companies forced to delist as regulatory scrutiny intensifies [1][6][10] Group 1: Delisting Trends - As of October 15, 2023, 13 companies have triggered mandatory delisting indicators due to major violations, marking a historical high [6][10] - Among these, 8 companies have already been delisted, including notable cases like Zhuolang Technology and Dongfang Group [6][10] - The delisting wave has highlighted the role of investment banks as gatekeepers, with 11 brokerage firms involved in the delisted companies [1][6] Group 2: Investment Banks' Responsibilities - Many problematic companies frequently changed their investment banks during periods of financial misconduct, complicating accountability [2][10] - Most involved investment banks issued "no objection" or "no issues found" reports during the supervision period, raising questions about their diligence [2][10] - The regulatory environment is pushing investment banks to reassess their responsibilities and improve their oversight practices [2][15] Group 3: Case Studies of Violations - ST Dongtong, involved in financial fraud from 2019 to 2022, had its investment bank, First Capital, implicated in fraudulent activities during a stock issuance [8][12] - Guohua Securities was the only firm to issue a risk warning regarding Jiuyou Co., while others remained silent despite ongoing fraud investigations [12][13] - Highong Data had the longest duration of fraud (2015-2023) and changed investment banks multiple times, indicating a pattern of evasion [10][11] Group 4: Regulatory Impact on Investment Banks - The shift towards stricter regulations has led to increased scrutiny of investment banks' roles, with many now enhancing their due diligence processes [15] - Investment banks are reportedly increasing their manpower and resources dedicated to ongoing supervision, reflecting a shift in focus due to regulatory pressures [15]

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-122 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第十四次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 江苏吴中医药发展股份有限公司(以下简称"公司")因涉嫌信息披露违 法违规，被中国证券监督管理委员会（以下简称"中国证监会"）立案 调查。2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先 告知书》（处罚字〔2025〕58 号）。认定公司虚增营业收入、营业成本 和利润，2020 年至 2023 年年度报告存在虚假记载，触及重大违法强制 退市情形。公司股票已于 2025 年 7 月 14 日起被叠加实施重大违法类强 制退市风险警示。 如根据正式的处罚决定书结论，公司触及重大违法强制退市情形，公司 股票将被终止上市。根据《上海证券交易所股票上市规则》第 9.5.7 条、 第 9.5.8 条，如公司后续收到行政处罚决定书，显示公司触及重大违法 类强制退市情形，公司将申请停牌，并及时披露有关 ...

Core Viewpoint - The A-share market is experiencing an unprecedented wave of delistings due to major violations, with a record number of companies forced to delist as regulatory scrutiny intensifies [1][5]. Group 1: Regulatory Environment - The new delisting regulations that came into effect at the beginning of the year have led to a historical high of 13 companies reaching the mandatory delisting criteria for major violations as of October 15 [1][5]. - The regulatory environment is becoming increasingly stringent, with the China Securities Regulatory Commission (CSRC) enforcing stricter oversight on financial fraud and other illegal activities [4][6]. Group 2: Role of Investment Banks - Eleven investment banks are under scrutiny for their roles in the delisted companies, with only two, First Capital and Wumart Securities, currently facing regulatory action [2][7]. - The complexity of the investment banks' responsibilities is highlighted by the fact that many of the involved companies frequently changed their advisory firms during periods of fraud [4][9]. Group 3: Case Studies of Delisted Companies - Notable cases include *ST Dongtong, which was involved in fraudulent activities from 2019 to 2022, leading to warnings issued to its sponsor, First Capital [7][8]. - Guandao Digital inflated its revenue by 1.465 billion yuan through fraudulent contracts and invoices, resulting in penalties for Wumart Securities, which served as its sponsor [8]. Group 4: Investment Banks' Due Diligence - Many investment banks provided "no objection" reports during the supervision periods of companies that were later found to have committed fraud, raising questions about their diligence [4][12]. - National Securities was the only firm to explicitly warn of risks associated with a client, indicating a lack of proactive risk management among other firms [12][13]. Group 5: Changes in Oversight Practices - Investment banks are reportedly increasing their efforts in due diligence, particularly during the ongoing supervision phases, in response to heightened regulatory scrutiny [15]. - Accounting firms are also enhancing their audit processes, adding independent review steps and increasing personnel to ensure thorough examinations [15].